Purchase Order 75N95022P00694
Award Date
9/16/22
Potential Completion Date
9/18/24
Potential Value
$150K
Federal Agency
National Institute on Drug Abuse
Ultimate Awardee
Not listed
PSC Category
Q301 - Reference Laboratory Testing
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
New York, NY 10019, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The Department of Health and Human Services National Institutes of Health National Institute on Drug Abuse awarded a $224,000.00 firm fixed price purchase order contract to the New York Stem Cell Foundation Inc., a non-profit organization. The contract is for the foundation to provide services including generating induced pluripotent stem cell lines from patients with Alzheimer's disease and related dementias, differentiating stem cells into insulin-producing beta cells, and expanding,...
This is a $249,750.00 firm fixed-price definitive contract awarded by the Department of Health and Human Services National Institutes of Health National Institute on Drug Abuse to the New York Stem Cell Foundation Inc., a non-profit organization. The contract is for services related to stem cell research, including generating induced pluripotent stem cell lines, differentiating stem cells, and expanding and validating neural progenitor cells from patients with conditions such as Alzheimer's...
The Department of Health and Human Services' National Institutes of Health National Institute on Drug Abuse awarded a $105,000 firm fixed price purchase order to New York Stem Cell Foundation Inc. as the prime contractor. The contract is to support the agency's research efforts and will be performed in New York, New York over a one year period from September 2023 through September 2024. No major subcontractors or set aside designations were indicated. The National Institute on Drug Abuse...
This is a $15,375 firm-fixed-price purchase order contract awarded by the National Human Genome Research Institute, a civilian agency within the Department of Health and Human Services, to the New York Stem Cell Foundation, Inc., a non-profit organization. The contract is for services related to stem cell research, including generating induced pluripotent stem cell lines from patients with Alzheimer's disease and related dementias, differentiating stem cells into insulin-producing beta cells,...
This is a $241,500 firm fixed price contract awarded by the National Institute on Drug Abuse (NIDA), a component of the U.S. Department of Health and Human Services, to the New York Stem Cell Foundation Inc., a non-profit organization. The contract is for the generation and characterization of human induced pluripotent stem cells (iPSCs), neural progenitor cells (NPCs), and stable transgenic iPSC lines from individuals with mood and anxiety disorders. This contract does not have a set-aside...
This $238,000.00 firm-fixed price purchase order was awarded by the Department of Health and Human Services' National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases to the New York Stem Cell Foundation, Inc., a non-profit organization that conducts stem cell research. The contract is for the derivation of induced pluripotent stem cells, which aligns with the foundation's work in generating stem cell lines, differentiating them into various cell types, and...
The Department of Health and Human Services' National Institutes of Health's National Human Genome Research Institute awarded a $986,250 firm fixed price purchase order to New York Stem Cell Foundation Inc. to provide beta cell differentiation and cell assay services. Under this two-year contract set to run from July 2020 through July 2022, New York Stem Cell Foundation will deliver products and services supporting the NIH's genomic research efforts, including differentiation of beta cells and...
<p>The National Institute on Drug Abuse (NIDA), a civilian agency, awarded a $183,731.46 firm-fixed-price purchase order contract to Oxford Stemtech LTD for scientific support services related to the generation and multiomics profiling of induced pluripotent stem cell-derived neuronal models. The contract does not have a set-aside designation, and the ultimate completion date is September 10, 2025. This contract award is not associated with a larger acquisition vehicle.</p>
This is a $1,399,499.93 firm fixed-price definitive contract awarded by the National Eye Institute, a civilian agency within the Department of Health and Human Services, to the New York Stem Cell Foundation Inc., a non-profit organization. The purpose of this contract is to obtain induced pluripotent stem cells (iPSCs) to advance the study of the functional basis of genetic variants associated with age-related macular degeneration (AMD). No set-aside designation was used for this award. The...
This is a $79,442.40 firm fixed-price purchase order contract awarded by the National Institute on Drug Abuse (NIDA), a civilian agency under the Department of Health and Human Services, to Rutgers, The State University. The contract is for the creation of induced pluripotent stem cells, which are a type of stem cell that can be derived from adult cells. The contract does not have a set-aside designation. Rutgers, a major public research institution, has a long history of receiving federal...